Who we are
Draupnir Bio is a Danish biotechnology company developing small molecule therapeutics to transform the treatment of heart disease. The company was founded in 2017 as a spin-out from Aarhus University, Denmark, and the Max-Planck Society, Germany.
Meet our team
Our team at Draupnir Bio is driven by a deep commitment to scientific excellence, and by the desire to bring innovative therapies to patients.
Scientific Advisory Board
Get to the heart of what we’re doing here at Draupnir Bio to transform the treatment of heart disease.
Draupnir Bio is a spin out from Aarhus University and the Max-Planck Society based on the breakthrough scientific findings of Professors Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, and Peter Seeberger.